Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, IBI310 and Lenvatinib for Organ Preservation in dMMR/MSI-H Gastric or Colon Cancers
NCT06580574Phase 2Recruiting
- Sponsor
- Peking University
- Start
- Sep 2024
- Primary completion
- Jun 2029
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, IBI310, lenvatinib in gastric cancer (GC), colon cancer, sponsored by Peking University. Started Sep 2024; status: recruiting.
02
Drugs
sintilimabIBI310lenvatinib
03
Conditions
gastric cancer (GC)colon cancer
Beyond the preview
Go deeper on NCT06580574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06580574.